Care of patients with severe insulin resistance (historically defined as a total daily insulin requirement of \>200 units/day) requires a great deal of time and resources due to challenging complex regimens delivered in multiple daily injections that often do not achieve individualized glycemic targets.^[@bibr1-0145721717701579]^ These high-dose, insulin-treated patients can experience reduced injection burden and improved glycemic control with the use of human regular U-500 insulin (U-500R).^[@bibr1-0145721717701579][@bibr2-0145721717701579][@bibr3-0145721717701579][@bibr4-0145721717701579]-[@bibr5-0145721717701579]^

Despite the introduction of the human formulation of regular U-500 insulin to the US market in 1997 and the 9.8 fold-increase in its use from 2005 to 2013,^[@bibr6-0145721717701579]^ limited evidence-based guidance has been available to inform its application. The first robustly powered titration-to-target randomized clinical trial (RCT) with U-500R^[@bibr1-0145721717701579],[@bibr2-0145721717701579],[@bibr7-0145721717701579],[@bibr8-0145721717701579]^ studied U-500R initiation and titration algorithms for patients with severely insulin-resistant type 2 diabetes. While the trial results were beneficial in terms of efficacy and safety, the trial protocol was highly structured, intensive, and not specifically designed for the day-to-day clinical setting. A practical translation of the U-500R trial results and learnings is therefore needed to assist diabetes teams in the management of their U-500R-treated patients in the clinical setting.

The American Diabetes Association recommends the use of a team-based care model (planned visits, self-management support, and evidence-based decision support) in the treatment of diabetes. Team-based care is both coordinated and proactive.^[@bibr9-0145721717701579]^ Despite evidence of the value of diabetes self-management education, utilization and reimbursement are lacking^[@bibr10-0145721717701579],[@bibr11-0145721717701579]^ in contrast to a rising prevalence of obesity, insulin resistance, and type 2 diabetes.^[@bibr12-0145721717701579][@bibr13-0145721717701579][@bibr14-0145721717701579]-[@bibr15-0145721717701579]^ Combined with declining numbers of clinical endocrinologists,^[@bibr16-0145721717701579]^ the US health care system's ability to provide comprehensive and timely care for patients with type 2 diabetes is strained.

In alignment with these recommendations,^[@bibr9-0145721717701579]^ a team-based approach utilizing the diabetes educator's skills is proposed for transitioning patients with severe insulin resistance to U-500R therapy. This article provides clinically relevant suggestions and useful teaching materials adapted from dosing algorithms used in the U-500R titration-to-target trial^[@bibr1-0145721717701579]^ with emphasis on the multidisciplinary team in diabetes management. The benefit of a close collaboration between an expert prescriber who determines the initial U-500R dose and the diabetes educator who provides dose titration and ongoing diabetes self-management education is underscored. A program as such would reduce the time and resource burden on the expert prescriber for this population by leveraging the expertise, resources, and patient interactions of the diabetes educator during the transition to this highly concentrated insulin.^[@bibr16-0145721717701579]^

Time-Action Profile of Human Regular U-500 Insulin {#section3-0145721717701579}
==================================================

The pharmacokinetic/pharmacodynamic (PK/PD) characteristics of U-500R in obese healthy subjects have been studied^[@bibr17-0145721717701579],[@bibr18-0145721717701579]^ and reviewed^[@bibr3-0145721717701579]^ in prior publications. Simulation modeling to steady-state supports the unique short-acting prandial and longer-acting basal activity of high-dose U-500R for use as insulin monotherapy administered twice-daily (BID) or three-times-daily (TID) and predicts attainment of steady-state within 24 hours after dosage increases.^[@bibr18-0145721717701579]^ When administered at same higher doses (50 units \[0.4-0.6 units/kg\] and 100 units \[0.8-1.3 units/kg\]), absorption from the subcutaneous injection site and time to effect (\<20 minutes) are similar between human regular U-100 insulin (U-100R) and U-500R;^[@bibr17-0145721717701579]^ however, the peak concentration of U-500R is lower, its time to peak effect is longer (\~6 hours vs \~5 hours^[@bibr17-0145721717701579]^), and its duration of action is more prolonged (up to 24 hours^[@bibr17-0145721717701579],[@bibr19-0145721717701579]^ vs \~18 hours).^[@bibr17-0145721717701579]^ This is in contrast to the time to peak effect (\~3 hours) and duration of action (\~8 hours) observed with the administration of U-100R at lower doses (0.05-0.4 units/kg),^[@bibr20-0145721717701579]^ consistent with the known dose dependency of insulin PK/PD.^[@bibr21-0145721717701579]^ Despite this available evidence, some clinicians continue to believe that U-500R is better absorbed than high-dose U-100 insulins^[@bibr22-0145721717701579],[@bibr23-0145721717701579]^ and that U-500R has only basal^[@bibr22-0145721717701579]^ or intermediate-acting^[@bibr23-0145721717701579],[@bibr24-0145721717701579]^ insulin properties.

Prior U-500R Dosing Recommendations {#section4-0145721717701579}
===================================

Prior to the U-500R titration-to-target trial,^[@bibr1-0145721717701579]^ clinicians had only their own clinical experience and largely retrospective, nonrandomized case reports/series,^[@bibr25-0145721717701579][@bibr26-0145721717701579][@bibr27-0145721717701579][@bibr28-0145721717701579]-[@bibr29-0145721717701579]^ real-world evidence studies,^[@bibr30-0145721717701579][@bibr31-0145721717701579]-[@bibr32-0145721717701579]^ and clinical reviews^[@bibr3-0145721717701579][@bibr4-0145721717701579]-[@bibr5-0145721717701579],[@bibr33-0145721717701579][@bibr34-0145721717701579][@bibr35-0145721717701579][@bibr36-0145721717701579]-[@bibr37-0145721717701579]^ to inform U-500R use. Treatment approaches varied among clinicians and experts, with some initiating U-500R with 1-to-1 total daily dose (TDD) transition (U-100 insulins to U-500R) evenly split over multiple daily doses (BID, TID, or 4-times-daily \[QID\]). Others adjusted the initial starting doses by varying formulas (reduced by 10%-20% depending on baseline glycated hemoglobin \[A1C\]) to minimize hypoglycemia or accelerate glycemic improvement with various initial dosage proportions.

The U-500R Titration-to-Target RCT: Summary of Design and Results {#section5-0145721717701579}
=================================================================

This was a 24-week, multicenter, open-label, parallel, titration-to-target trial that enrolled overweight to severely obese patients with uncontrolled type 2 diabetes (A1C: 7.5%-12% \[58-108 mmol/mol\]) on high-dose U-100 insulins (TDD 201-600 units) with or without oral antihyperglycemic medications.^[@bibr1-0145721717701579]^ The study followed a very structured initiation and titration protocol that called for a reduction in the initial U-500R dose by 20% of the U-100 insulin TDD for patients with an A1C ≤8% (≤64 mmol/mol) or mean plasma glucose \<183 mg/dl (\<10.16 mmol/l) (estimated average glucose for an A1C of 8% \[64 mmol/mol\]^[@bibr38-0145721717701579]^) within the 7 days before randomization. For patients with an A1C \>8% (\>64 mmol/mol) or mean plasma glucose ≥183 mg/dl (≥10.16 mmol/l), the U-500R starting dose was 100% of the U-100 insulin TDD. The U-500R TDD was then divided into 60:40 (%) proportions for BID (pre-breakfast:pre-evening meal) dosing or 40:30:30 (%) proportions for TID (pre-breakfast:pre-lunch:pre-evening meal) dosing. Titration intervals (phone and office visits) were weekly for the first 6 weeks, then biweekly for 6 weeks, then every 3 weeks for the final 12 weeks. Both BID doses and 2 of the 3 TID doses with the greatest need for adjustment could either be increased by 5% to 15% for hyperglycemia or be reduced by 10% for hypoglycemia (≤70 mg/dl \[≤3.89 mmol/l\]) based on the median of the 3 most recent self-monitored plasma glucose (SMPG) readings for each measured time point, with hypoglycemia prioritized over hyperglycemia for safety.

Key efficacy and safety results of the U-500R titration-to-target trial^[@bibr1-0145721717701579]^ are summarized in [Table 1](#table1-0145721717701579){ref-type="table"}. In brief, change from baseline to 24-week endpoint reductions in A1C were clinically equivalent (1.1%-1.2% \[12-13 mmol/mol\]) with a similar low incidence of severe hypoglycemia and similar modest weight gain across BID and TID treatment arms and a higher incidence of nonsevere hypoglycemia in the BID group ([Table 1](#table1-0145721717701579){ref-type="table"}). Importantly, no rescue therapy (BID to TID or TID to QID) for persistent, uncontrolled hyperglycemia was required. Endpoint proportions were also very close to beginning proportions in each arm with similar increases in U-500R TDDs ([Table 1](#table1-0145721717701579){ref-type="table"}). Patient-reported outcomes assessed in the trial showed that transitioning from high-dose, high-volume U-100 insulins to either BID or TID U-500R regimen lessened injection site discomfort, improved patient perception of insulin use and impact of diabetes treatment on daily life function and psychological health, and increased adherence, particularly with BID administration.^[@bibr2-0145721717701579]^

###### 

Key 24-Week Outcomes in the Human Regular U-500 Insulin Titration-to-Target RCT^[a](#table-fn1-0145721717701579){ref-type="table-fn"}^

![](10.1177_0145721717701579-table1)

                                                                                                         TID (n = 162)                                                  BID (n = 161)                                                  *P* Value^[b](#table-fn2-0145721717701579){ref-type="table-fn"}^
  ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------
  Efficacy                                                                                                                                                                                                                             
   Endpoint measure                                                                                                                                                                                                                    
    A1C (%)                                                                                              7.5                                                            7.4                                                            
     CFB (primary endpoint)                                                                              −1.1^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^    −1.2^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^    .37
    A1C (mmol/mol)                                                                                       59.0                                                           57.0                                                           
     CFB (primary endpoint)                                                                              −12.0^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   −13.0^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   .37
    TDD (units)                                                                                          343.1                                                          335.0                                                          
     CFB                                                                                                 +55.2^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   +51.4^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   .79
    Fasting SMPG (mg/dl)                                                                                 149.1                                                          144.0                                                          
     CFB                                                                                                 −24.1^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   −29.2^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   .36
    Fasting SMPG (mmol/l)                                                                                8.28                                                           7.99                                                           
     CFB                                                                                                 −1.34^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   −1.62^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   .36
    Daily mean SMPG (mg/dl)                                                                              153.9                                                          150.4                                                          
     CFB                                                                                                 −30.3^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   −34.9^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   .27
    Daily mean SMPG (mmol/l)                                                                             8.54                                                           8.35                                                           
     CFB                                                                                                 −1.68^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   −1.94^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^   .27
    Within-day glycemic variability^[d](#table-fn4-0145721717701579){ref-type="table-fn"}^ CFB, median   −2.0                                                           −3.3                                                           .03
  Safety                                                                                                                                                                                                                               
   Endpoint measure                                                                                                                                                                                                                    
    Severe hypoglycemia^[e](#table-fn5-0145721717701579){ref-type="table-fn"}^                                                                                                                                                         
     Incidence, n (%)                                                                                    3 (1.9)                                                        6 (3.7)                                                        .34
    Nonsevere hypoglycemia^[f](#table-fn6-0145721717701579){ref-type="table-fn"}^                                                                                                                                                      
     Documented symptomatic (≤70 mg/dl \[≤3.89 mmol/l\])                                                                                                                                                                               
      Incidence, n (%)                                                                                   149 (92.0)                                                     145 (90.1)                                                     .003
     Documented symptomatic (\<50 mg/dl \[\<2.78 mmol/l\])                                                                                                                                                                             
      Incidence, n (%)                                                                                   91 (56.2)                                                      103 (64.0)                                                     .09
     Documented symptomatic nocturnal (≤70 mg/dl \[≤3.89 mmol/l\])                                                                                                                                                                     
      Incidence, n (%)                                                                                   126 (77.8)                                                     130 (80.8)                                                     \<.001
     Documented symptomatic nocturnal (\<50 mg/dl \[\<2.78 mmol/l\])                                                                                                                                                                   
      Incidence, n (%)                                                                                   59 (36.4)                                                      79 (49.1)                                                      .046
    Weight (kg)                                                                                          125.5                                                          128.5                                                          
     CFB                                                                                                 +5.4^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^    +4.9^[c](#table-fn3-0145721717701579){ref-type="table-fn"}^    .34

Data are presented as means for endpoint values and least squares means for change from baseline to endpoint values unless otherwise stated. A1C, glycated hemoglobin; BID, twice daily; CFB, change from baseline; SMPG, self-monitored plasma glucose; TDD, total daily dose; TID, 3 times daily.

*P* values are from BID versus TID treatment comparisons.

*P* \< .05 for within-treatment CFB.

SD of 7-point SMPG.

Severe hypoglycemia was defined as any hypoglycemic episode requiring assistance from another person and accompanied by neurologic/cognitive impairment.

Nonsevere hypoglycemic events were categorized as documented symptomatic, nocturnal, or asymptomatic. Documented symptomatic hypoglycemia was defined as 1 or more signs/symptoms typically associated with hypoglycemia accompanied by an SMPG of ≤70 mg/dl or \<50 mg/dl. Nocturnal hypoglycemia was defined as any documented symptomatic event occurring between bedtime and waking. Asymptomatic hypoglycemia was defined as any measured SMPG ≤70 mg/dl or \<50 mg/dl not accompanied by hypoglycemic signs/symptoms.

Learnings From the U-500R Titration-to-Target RCT Applied to Clinical Practice {#section6-0145721717701579}
==============================================================================

Initiation of U-500R {#section7-0145721717701579}
--------------------

Initiation of U-500R begins with the calculation of the total of all insulins and then converting to the U-500R beginning doses ([Figures 1](#fig1-0145721717701579){ref-type="fig"} and [2](#fig2-0145721717701579){ref-type="fig"}). It is recommended that the prescriber confirms the patient's actual home doses to compare with prescribed doses. Complex insulin regimens (up to 10 injections per day)^[@bibr1-0145721717701579]^ can increase patient burden and decrease adherence of all prescribed daily doses.^[@bibr2-0145721717701579],[@bibr3-0145721717701579],[@bibr30-0145721717701579],[@bibr31-0145721717701579]^ When switching to U-500R, if the prescriber neglects to determine the true home doses being administered and a much higher initial U-500R dose is prescribed, the patient is at an increased risk for hypoglycemia in the early transition period.

![Twice-daily initiation doses. Initial doses are carried over to titration tool at visit 1 ([Figure 4](#fig4-0145721717701579){ref-type="fig"}) to calculate a new dose ([Figure 5](#fig5-0145721717701579){ref-type="fig"}). Color coded for guidance: all pre-breakfast doses in blue sections; all pre-evening meal doses in green sections.](10.1177_0145721717701579-fig1){#fig1-0145721717701579}

![Three-times-daily initiation doses. Initial doses are carried over to titration tool at visit 1 ([Figure 4](#fig4-0145721717701579){ref-type="fig"}) to calculate a new dose ([Figure 3](#fig3-0145721717701579){ref-type="fig"}). Color coded for guidance: all pre-breakfast doses in blue sections; all pre-lunch doses in yellow sections; all pre-evening meal doses in green.](10.1177_0145721717701579-fig2){#fig2-0145721717701579}

To simplify the protocol for the clinical setting, a conservative recommendation is to reduce the initial U-500R TDD by 20% of the U-100 insulin TDD with conventional rounding to the nearest 5 units for all patients (as opposed to what was done in Hood et al^[@bibr1-0145721717701579]^) to account for possible nonadherence to prescribed U-100 ([Figures 1](#fig1-0145721717701579){ref-type="fig"} and [2](#fig2-0145721717701579){ref-type="fig"}). As discussed in the titration section, frequent interactions and titrations with the diabetes educator during the dosage adjustment stage will allow for up-titration and compensate for any early underdosing. The prescriber may also opt to individualize the initial U-500R dosing according to patient factors such as A1C,^[@bibr1-0145721717701579],[@bibr7-0145721717701579]^ adherence to prior insulin regimen, age, coexisting comorbidities, hypoglycemic tendencies, and so on.^[@bibr39-0145721717701579][@bibr40-0145721717701579][@bibr41-0145721717701579][@bibr42-0145721717701579][@bibr43-0145721717701579]-[@bibr44-0145721717701579]^

Once the initial U-500R TDD is determined, clinicians then decide which dosing regimen to use and dose proportions. The U-500R titration-to-target trial^[@bibr1-0145721717701579],[@bibr7-0145721717701579]^ demonstrated clinically equivalent results between the BID and TID dosing arms. Three-times-daily dosing demonstrated slightly lower nonsevere hypoglycemia, particularly at night ([Table 1](#table1-0145721717701579){ref-type="table"}), while BID dosing provided less injection burden, a simpler regimen, and a simplified titration.^[@bibr1-0145721717701579],[@bibr2-0145721717701579]^ In the prespecified TDD subgroup analysis,^[@bibr7-0145721717701579]^ no differences were found in efficacy or safety between BID and TID dosing regardless of baseline U-100 insulin TDD, so higher-dose U-500R is not a reason to use TID over BID dosing. Given the clinical equivalency of efficacy and safety of BID versus TID, there is no reason necessarily to recommend U-500R TID specifically because a patient eats lunch and a belief in the need to "cover" the lunch post-prandial glucose. For these reasons and to simplify the protocol for use in clinical practice, BID dosing and titration are the focus of this review. For further details on TID initiation dosing and titration, tools are provided in [Figures 2](#fig2-0145721717701579){ref-type="fig"} and [3](#fig3-0145721717701579){ref-type="fig"}. Dose proportions (%) of 60:40 for BID and 40:30:30 for TID are recommended for initial dosing (as supported by trial endpoint proportions^[@bibr1-0145721717701579]^).

![Three-times-daily titration tool. Color coded for guidance: all pre-breakfast doses in blue sections; all pre-lunch doses in yellow sections; all pre-evening meal doses in green sections.](10.1177_0145721717701579-fig3){#fig3-0145721717701579}

Titration of U-500R {#section8-0145721717701579}
-------------------

[Figure 4](#fig4-0145721717701579){ref-type="fig"} shows a recommended flow diagram for the U-500R management plan adapted from the U-500R titration-to-target trial.^[@bibr1-0145721717701579]^ Considering that efficacy and safety results of this trial occurred in an investigative site environment with frequent contact and dose adjustments, it is important to note that the first 12 weeks are crucial for dosage titration and patient safety. Initial weekly and biweekly contact may be impractical and resource restrictive for many prescribers. Thus, the partnership of the diabetes educator with the prescriber and other diabetes team members can provide the needed connection and support between the quarterly diabetes office visits and A1C measurements ([Figure 4](#fig4-0145721717701579){ref-type="fig"}) and provide the necessary frequent patient contact. After the initial dose is calculated, the patient is referred to the diabetes educator for a thorough patient assessment of knowledge, self-management skills, and behaviors and attitudes for the planning, implementation, and titration of the regimen. Based on this assessment, the diabetes educator should provide individualized education and support consisting of a minimum of sick day management, glucose monitoring, activity, and meal planning while making appropriate insulin dose adjustments during the frequent initial contacts, which may be more frequent than weekly in some practices (eg, St Elizabeth Physicians, Covington, Kentucky \[P.M.B., W.E.E.\]). For the diabetes educator who is not an advanced practice provider or physician, written orders or signed protocol for titration must be obtained.

![Recommended visit schedule for the diabetes management team collaboration.](10.1177_0145721717701579-fig4){#fig4-0145721717701579}

Titration in the U-500R titration-to-target trial for both BID and TID treatment arms was based on the prandial/basal characteristics of U-500R identified in pharmacology studies^[@bibr17-0145721717701579],[@bibr18-0145721717701579]^ and reinforced in the trial.^[@bibr1-0145721717701579]^ [Figure 5](#fig5-0145721717701579){ref-type="fig"} provides recommendations for revising the trial BID titration algorithm for clinical application. Doses should be titrated according to mean preprandial glucose readings of the subsequent meal (ie, evening meal dose titrated according to pre-breakfast glucose reading). However, hypoglycemia at bedtime (mean SMPG \<80 mg/dl \[4.44 mmol/l\]) or at 3 am (single SMPG \<80 mg/dl \[4.44 mmol/l\]) should result in a 10% evening meal dose reduction even in the event of above target mean premeal glucose readings (hypoglycemia is prioritized over hyperglycemia). Both doses for the BID regimen should be titrated at each visit. Changing from BID to TID dosing may be considered if the patient experiences overnight hypoglycemia or for those who eat lunch and the glucose pattern suggests significant post-prandial excursions despite adjustments of the breakfast dose.

![Twice-daily titration tool. Color coded for guidance: all pre-breakfast doses in blue section; all pre-evening meal doses in green section.](10.1177_0145721717701579-fig5){#fig5-0145721717701579}

An important distinction in the U-500R titration-to-target trial was use of *percentage* dose adjustments versus *numerical* titrations.^[@bibr1-0145721717701579]^ This was based on the wide range of initial U-100 insulin TDDs (201-600 units) in study participants and the anticipated increases in U-500R TDDs in patients who were quite under-insulinized at randomization. For example, a numerical adjustment of 5 to 15 units per dose per visit would have a much different effect if applied to a patient on a 70-unit pre-meal dose versus a patient requiring 200 units pre-meal. Accordingly, use of 5% to 15% dosage increases for corresponding glucose readings above target and 10% decreases for readings below target is recommended ([Figures 3](#fig3-0145721717701579){ref-type="fig"} and [5](#fig5-0145721717701579){ref-type="fig"}).

The U-500R titration-to-target trial^[@bibr1-0145721717701579]^ used the median of the 3 most recent glucose measurements for pre-meal and pre-bedtime readings (median was not used for hypoglycemic readings at 3 am). For patients using a paper log, this may still be considered for ease of calculations. However, with the current access of most patients to glucose monitors with data history and download capabilities, many clinicians have access to software to calculate pre-meal, bedtime, and 3 am glucose means. Cloud-based software systems allow patients to upload at home and the health care provider to view from any computer. Due to this access, the proposed titration adjustments for corresponding glucose readings use a 7-day mean ([Figures 3](#fig3-0145721717701579){ref-type="fig"} and [5](#fig5-0145721717701579){ref-type="fig"}). For missing glucose data, it is essential to assess the reason for the lack of readings and educate the patient on the importance of glucose monitoring to accomplishing U-500R titration. There should be a minimum of 3 readings before a dosing change is made. Otherwise, no change is made.

The glycemic target range of 71 mg/dl to 130 mg/dl (3.94-7.22 mmol/l) was used in the U-500R titration-to-target trial,^[@bibr1-0145721717701579]^ as recommended by the American Diabetes Association in 2012,^[@bibr45-0145721717701579]^ the year the study protocol was approved. These guidelines were changed in 2014 to suggest a target range of 80 mg/dl to 130 mg/dl (4.44-7.22 mmol/l),^[@bibr46-0145721717701579]^ and accordingly, the recommended titration algorithms for translation to the practice setting have been modified to reflect this change ([Figures 3](#fig3-0145721717701579){ref-type="fig"} and [5](#fig5-0145721717701579){ref-type="fig"}). However, the target range may be individualized based on patient characteristics (eg, duration of diabetes, comorbidities, age/life expectancy, hypoglycemia unawareness).^[@bibr42-0145721717701579]^ The cutoff for 10% reduction in doses has been modified from ≤70 mg/dl (≤3.89 mmol/l) to \<80 mg/dl (\<4.44 mmol/l), which should reduce the occurrence of hypoglycemia. Intervals for each dosage increase have also been simplified to 50 mg/dl (2.78 mmol/l). It is understood that these modifications to the U-500R titration-to-target trial dosing algorithms may result in a less steep initial drop in A1C values if applied in the practice setting, possibly with less initial A1C lowering. Such a gradual reduction in A1C may be particularly beneficial to patients with long-standing, significant elevations in A1C who may experience subjective hypoglycemic symptoms with steep A1C reductions. The algorithms as modified will also still likely drive patients toward A1Cs approaching what was observed in the U-500R titration-to-target trial. Another very important point for application of the trial to clinical practice is that clinicians should modify titrations based on individualized patient targets for A1C^[@bibr9-0145721717701579],[@bibr40-0145721717701579],[@bibr41-0145721717701579],[@bibr43-0145721717701579],[@bibr44-0145721717701579]^ that may differ from the glycemic targets used in the study. For instance, if a patient's individualized A1C target is reached, it is reasonable to either suspend up-titration or adjust titration targets while continuing dosage reductions for hypoglycemia.

Glucose Monitoring {#section9-0145721717701579}
------------------

Patients need to perform glucose monitoring before meals and at bedtime^[@bibr1-0145721717701579],[@bibr47-0145721717701579]^ while on U-500R. Of note, some insurance providers may require a prior approval for the number of test strips required for this frequency of testing (eg, Medicare^[@bibr48-0145721717701579]^ limits to 100 strips/month for insulin users without a medical necessity letter). Early morning (2 am or 3 am) readings should be measured within 2 days of any dosage change. Individualized call parameters for hypoglycemia and hyperglycemia should be determined. Each patient should be encouraged to call when these parameters are reached and to not delay reporting until the next visit. Correction dosing (pre- or post-meal) according to an insulin sensitivity factor is not recommended due to risk of stacking and increased risk of hypoglycemia, particularly when patients are approaching their target A1C. Professional continuous glucose monitoring may be utilized to assist with the monitoring and titration of individual U-500R doses (during the 12-week initiation and titration phase or at the first follow-up visit after doses have stabilized) and is particularly helpful in identifying nocturnal hypoglycemia or providing glucose data if the A1C does not correspond with glucose results (suggesting post-prandial highs or lows).

Additional Clinical Pearls {#section10-0145721717701579}
==========================

Choosing Appropriate Patients for U-500R {#section11-0145721717701579}
----------------------------------------

Not every patient with severely insulin-resistant diabetes is a good candidate for use of U-500R. Although 20% of patients enrolled in the U-500R titration-to-target trial were ≥65 years of age, one BID-assigned 72-year-old patient died from irreversible brain injury after experiencing seizure/coma from presumed prolonged severe hypoglycemia after 21 weeks of follow-up.^[@bibr1-0145721717701579]^ This patient lived alone, had a history of missing 7-point SMPG profiles and 3 am readings, and had a history of major cardiovascular disease. Those with history of poor adherence with office visits or glucose monitoring, hypoglycemic unawareness, extreme age with major chronic debilities, cognitive or psychiatric impairment, or extreme meal patterns (ie, 1 meal per day or excessive grazing) may be judged to be inappropriate for U-500R.

Concomitant Therapy {#section12-0145721717701579}
-------------------

Concomitant use of other insulins with U-500R is not recommended or necessary based on the U-500R time-action profile (see Time-Action Profile section) and as demonstrated in the U-500R titration-to-target trial^[@bibr1-0145721717701579]^ and prior case reports/series and reviews.^[@bibr3-0145721717701579][@bibr4-0145721717701579]-[@bibr5-0145721717701579],[@bibr25-0145721717701579][@bibr26-0145721717701579][@bibr27-0145721717701579][@bibr28-0145721717701579]-[@bibr29-0145721717701579],[@bibr33-0145721717701579][@bibr34-0145721717701579][@bibr35-0145721717701579][@bibr36-0145721717701579]-[@bibr37-0145721717701579]^ This practice complicates the regimen for patients and makes it more costly^[@bibr30-0145721717701579][@bibr31-0145721717701579]-[@bibr32-0145721717701579]^ (often including multiple co-pays) but is still quite prevalent.^[@bibr32-0145721717701579]^ Use of other antihyperglycemic agents (other than secretagogues) with U-500R can follow clinical guidelines (ADA/EASD^[@bibr39-0145721717701579],[@bibr41-0145721717701579]^ and AACE/ACE^[@bibr40-0145721717701579],[@bibr43-0145721717701579]^ Combined use of non-insulin injectables^[@bibr30-0145721717701579][@bibr31-0145721717701579]-[@bibr32-0145721717701579],[@bibr49-0145721717701579],[@bibr50-0145721717701579]^ or sodium-glucose cotransporter-2 inhibitors^[@bibr51-0145721717701579]^ has been increasingly common for high-dose insulin-treated patients and other patients as well; initiation and escalation of doses of U-500R for such patients may need to be modified to reduce the risk of hypoglycemia.

Education {#section13-0145721717701579}
---------

The 2015 joint position statement from the American Diabetes Association, American Association of Diabetes Educators, and Academy of Nutrition and Dietetics states that clear communication and effective collaboration between a provider, educator, and patient is critical to ensure appropriate care as well as progress toward mutually defined goals. Diabetes self-management education and support should occur when there is a new complicating factor such as a complicated medicine regimen^[@bibr52-0145721717701579]^ (as would be the case with initiation of U-500R). Diabetes self-management for sick days, alcohol ingestion, traveling, activity, and other diabetes education topics for patients treated with U-500R is not different from diabetes self-management for any patient treated with insulin unless as stated in the following for hypoglycemia and meal planning.

Although not accessible to all patients, an initial medical nutrition therapy visit along with follow-up visits as needed for healthy meal planning is strongly encouraged. Meals should be individualized based on the needs of the patient.^[@bibr53-0145721717701579]^ Consistent grams of carbohydrate at consistent meal times (using carbohydrate counting or the plate method) is recommended for patients treated with U-500R to reduce the risk of hypoglycemia. Patients who anticipate skipping a meal should decrease the U-500R dose by 50% for that meal (as was done in the U-500R titration-to-target trial)^[@bibr1-0145721717701579]^ in light of the known prandial/basal activity of U-500R. To decrease the risk of nocturnal hypoglycemia, a bedtime snack is recommended if bedtime glucose is ≤140 mg/dl (≤7.77 mmol/l). For bedtime glucose levels \>140 mg/dl (\>7.77 mmol/l), no snack is needed, but if desired, patients may choose a small snack with no carbohydrates to avoid nocturnal hyperglycemia. Large snacks, even non-carbohydrate, can result in a higher fasting glucose.

Hypoglycemia for patients on U-500R can be prolonged due to the long duration of action of the insulin. Patients should be instructed to check glucose for any signs or symptoms of hypoglycemia and to treat immediately for any glucose reading ≤70 mg/dl (≤3.89 mmol/l). A repeat BG reading within 15 minutes of treatment is recommended to assess for resolution of the hypoglycemia. Increased checking is recommended during the next 24 hours after a hypoglycemic event. Patients should be carefully instructed on hypoglycemia signs and symptoms and management, including prescribing of glucagon and instruction for family members. Instruct the patient to report hypoglycemia between visits and to not delay reporting in between phone or office contact. If a patient requires urgent or emergency care or is hospitalized, care providers should be notified of the use of U-500R, including doses in units of insulin. Patients should be provided with documentation (eg, identification card) of their current U-500R doses as well as contact information for the diabetes management team.

Administration {#section14-0145721717701579}
--------------

The prandial and basal properties of U-500R allow for administration as insulin monotherapy. Administration is recommended approximately 30 minutes before meals 2 or 3 times daily.^[@bibr19-0145721717701579]^ The U-500R titration-to-target trial^[@bibr1-0145721717701579]^ was conducted using the U-500R vial and non-dedicated U-100 insulin syringes. The U-500R prefilled pen and the 0.5 mL BD U-500 Insulin Syringe^[@bibr19-0145721717701579]^ have recently become available. Use of either dedicated device is strongly recommended for administration due to no dose conversion needed to deliver a dose (eg, dial with the pen or draw up with the U-500 insulin syringe to the 100-unit mark to get 100 units). The U-500 insulin syringe can be dosed up to 250 units per injection,^[@bibr54-0145721717701579]^ and the U-500R pen can be dosed up to 300 units per injection.^[@bibr55-0145721717701579]^ At study endpoint, patients in the U-500R titration-to-target trial had a mean TDD of \~339 units.^[@bibr1-0145721717701579]^ Most patients will not have an individual dose \>250 units. However, for patients on an extremely large TDD, they will require more than 1 injection per dose if individual doses exceed 250 units for U-500 insulin syringe or 300 units for U-500 pen. For a U-100 insulin syringe, the total dose of U-500R must be divided by 5 or multiplied by 0.2 to convert to unit markings (eg, the 20-unit marking = 100 units).^[@bibr4-0145721717701579]^ If the patient is using a tuberculin (volumetric) syringe, the total dose of U-500R must be divided by 500 or multiplied by 0.002 to convert to a dose in ml (eg, 0.2 ml = 100 units).^[@bibr4-0145721717701579]^ It is *crucially important* for the diabetes educator/diabetes team to explain dosing with the prescribed device (syringe or prefilled pen) and to assess and reassess understanding at each office visit and phone call to ensure the patient understands how to administer the dose correctly as well as the total U-500R dose prescribed. Visual assessment of patient technique is recommended frequently to assess for correct measurement, priming (for pen use), site selection, and depth and angle of injection.

Pharmacy Collaboration {#section15-0145721717701579}
----------------------

It is highly recommended to use a standardized prescription format. Prescribe the units per dose and indicate NO SUBSTITUTION to avoid substitution at the pharmacy of the U-100 syringe for the BD U-500 Insulin Syringe or a vial for pen. For patients using a non-dedicated device, include the units and unit markings for the device. Consult the pharmacist at initiation of U-500R to inform him or her about the titration methods being used and that frequent titrations will particularly occur in the first 12 weeks. This may help to reduce the number of pharmacy call-backs for clarification as well as provide the pharmacist with the knowledge of this intervention when counseling the patient during dispensing. The pharmacist can also be vital in reinforcing the importance of recognition and prompt treatment of hypoglycemia, including appropriate use of glucagon.

Patient Self-Titration {#section16-0145721717701579}
----------------------

Some offices may consider self-titration of doses by the patient. This has not been studied for U-500R in clinical trials or published case series and is only appropriate for the patient who is competent with glucose monitoring, provides weekly glucose data, attends all visits (phone or office), and can competently calculate and administer the appropriate doses. All offices may not feel comfortable allowing patients to self-titrate. A written patient/provider treatment plan agreement may be considered that includes a glucose monitoring schedule, meal planning instructions, dosing, and follow-up timing for both the diabetes educator and the prescriber.^[@bibr29-0145721717701579]^

Conclusion {#section17-0145721717701579}
==========

The U-500R titration-to-target trial^[@bibr1-0145721717701579]^ provides strong evidence-based support for the initiation and titration of U-500R as prandial/basal insulin monotherapy administered either BID or TID. The multidisciplinary diabetes team plays a crucial role in the management of these patients with severe insulin resistance; however, the complexity of the protocol and algorithms used in the U-500R study may be quite challenging for a busy office practice to apply. As such, this review presents recommended adaptations to the dosing protocol used in this trial for application to the clinical setting, which include initiation formulas and charts, titration worksheets, and an outpatient visit flow diagram emphasizing the utilization of the diabetes team. It also discusses dedicated and non-dedicated device options for U-500R administration and other clinical pearls. This information and these materials provide needed, timely, and practical assistance for the diabetes team in the care of this important group of patients with diabetes who require high-dose insulin therapy.
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